Covid vaccine: Covaxin Phase-3 efficacy data by March, says Bharat Biotech CMD

- The Bharat Biotech chairman Dr Krishna Ella also mentioned that there has been no interim analysis of the efficacy in the Phase 3 trials has been done so far
- 'Currently, we have 20 million doses. We are aiming to achieve 700 million doses capacity in four facilities,' he informed